Novo Nordisk Unveils 2030 Growth Strategy at Capital Markets Day; Shares Slide on Thin Details
- At its Sept. 21, 2026 Capital Markets Day in London, new CEO Mike Doustdar unveiled a strategy to scale Novo Nordisk's obesity franchise and diversify the pipeline beyond diabetes/obesity.
- Targets include 10x capacity for oral GLP-1 obesity therapy, serving more than 60 million patients globally by 2030, and launching 5+ "multi-blockbuster" products by 2030.
- Novo also set a goal of more than DKK150 billion (about $23 billion) in risk-adjusted pipeline sales by 2035, and pledged to be "more active" in business development (licensing/M&A) and direct-to-consumer sales models.
- The moves are aimed at addressing investor concern that Novo is too reliant on its GLP-1 franchise.
- Market reaction was negative: shares fell sharply intraday (reports of roughly 5-9%), as analysts said the plan was strong on ambition but thin on new specifics, amid rising competition from Eli Lilly's tirzepatide/Zepbound.
This is the payoff to last week's "Novo" rebrand, and the market just delivered its verdict: a 2030/2035 target set with no concrete near-term catalyst is guidance, not proof, so shares got sold rather than bought. The real signal isn't the capacity or blockbuster math — it's the pledge to get "more active" in business development. That's Doustdar admitting the internal pipeline can't diversify fast enough on its own, especially with Lilly's tirzepatide/Zepbound machine still taking share while Novo's oral GLP-1 scale-up remains years out. Ambition claims parity; execution proves it. The next real test isn't another investor-day slide — it's whether Doustdar actually closes a deal or lands an R&D readout in the coming quarters, or whether this was sentiment management dressed up as strategy.
With new strategy, Novo outlines plans for obesity, direct-to-consumer work ↗